Physician profile
James Modlinger
NPI 1770521056
$8,561.71
in general payments reported to CMS, 2019-2025
34 companies · $998 in 2025
The $998 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,169 · 2020: $525 · 2021: $1,173 · 2022: $1,082 · 2023: $938 · 2024: $1,676 · 2025: $998.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,593 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,592.63 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,118.42 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals Lp | $1,001.30 | 2019-2025 | Farxiga, Lokelma, Wainua |
| Amarin Pharma, INC. | $789.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $777.28 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $577.53 | 2019-2024 | Ozempic |
| Novartis Pharmaceuticals Corporation | $512.43 | 2019-2025 | |
| Abbott Laboratories | $422.93 | 2021-2024 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $384.37 | 2024-2025 | Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $360.76 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $332.13 | 2020-2025 | Amvuttra, Onpattro |
| Janssen Pharmaceuticals, INC | $253.31 | 2022-2024 | Xarelto |
| Esperion Therapeutics, INC. | $221.95 | 2020-2025 | Nexletol |
| Lilly USA, LLC | $221.74 | 2019-2022 | |
| Kiniksa Pharmaceuticals International, Plc | $174.80 | 2024 | Arcalyst |
| Pfizer INC. | $170.29 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $151.19 | 2023-2025 | Biomonitor, Amvia Edge, Acticor 7 Vr-T Dx |
| Silk Road Medical, INC. | $145.04 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $139.68 | 2024 | Inpefa |
| Madrigal Pharmaceuticals | $133.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $124.64 | 2019 | |
| Bardy Diagnostics, INC. | $92.76 | 2019-2022 | |
| Kiniksa Pharmaceuticals, Ltd. | $82.33 | 2022-2023 | Arcalyst |
| Corcept Therapeutics | $75.99 | 2024-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $71.98 | 2021-2023 | |
| Medtronic, INC. | $50.90 | 2022 | |
| Currax Pharmaceuticals LLC | $32.13 | 2024 | Contrave |
| Heartflow, INC. | $22.38 | 2023 | Ffrct |
| Alexion Pharmaceuticals, INC. | $22.34 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $19.64 | 2020 | |
| Vertiflex, INC. | $18.25 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.72 | 2023 | Edarbyclor |
| Eisai INC. | $15.61 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $14.05 | 2021 | |
| C2n Diagnostics, LLC | $13.67 | 2025 | Precivityad2 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Modlinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.